Objective: Neprilysin (NEP) is the dominant Ab peptidedegrading enzyme in the brain. HIV-1 subtype B transactivator of transcription protein is known to interfere with NEP function, but whether this is true of HIV-1C transactivator of transcription, which has a defective chemokine motif, is not known. This study aimed to analyze the impact of HIV subtype on NEP-mediated cleavage of Ab by comparing cerebrospinal fluid (CSF) and serum levels of NEP between HIV+ (27 patients with HIV-1B and 26 with HIV-1C), healthy HIV2 controls (n = 13), and patients with Alzheimer disease (n = 24).
T he interactions between HIV and aging are an increasingly important topic. Because the introduction of highly active antiretroviral therapy, patients with HIV infection (HIV+) have been living longer with an improved quality of life and decreased morbidity. 1 We face an increase in the age of the HIV-1-infected population, which is not only due to effective antiretroviral therapy (ART) but also to new infections among older people. In addition, HIV-infected patients show aging signs earlier, chronic HIV-infection results in epigenetic increase in biological age. 2 HIV-1-infected cells actively secrete the viral protein transactivator of transcription (Tat). 3 Tat has been found in the brain of patients with HIV-1 infection, and amyloid b (Ab) staining was significantly increased in human brain from individuals with HIV-1 infection compared with controls. 4, 5 Tat inhibits neprilysin (NEP)-mediated cleavage of Ab peptide; the inhibitory function of NEP depends on the Tat "CC" dimotif. 6, 7 Tat in patients with HIV1-subtype C (HIV1-C) has defective chemokine activity 8, 9 because of replacement of the CC dimotif with serine, CS, or SC. 9 It is not known how the HIV1-C-defective Tat interferes with NEP function; this was the first study to analyze NEP in patients with HIV1-C.
NEP becomes inactivated and down-regulated during both the early stages of Alzheimer disease (AD) and in normal aging. 10 Reduced cerebrospinal fluid (CSF) NEP activity levels have been shown to occur in early AD, suggesting that altered CSF NEP activity levels may also be associated with dementia and lowered levels of CSF Ab-42. 6, 11 The aim of this study was to analyze the impact of the HIV1-C subtype, as a proxy for the defective CC dimotif, on NEP activation levels, compared with HIV1-B. We also compared the CSF levels of NEP between HIV+, healthy HIV2 controls, and patients with AD. An in vitro study showed that the exposure to HIV-1 Tat subtype B decreased protein and mRNA levels of NEP and zonula occludens-1 in human cerebral microvascular endothelial (HBEC-5i) cells culture, as well as increased transendothelial transfer of Ab and intracellular reactive oxygen species levels. These results suggest that the Ras signaling pathway is involved in HIV-1 Tat-induced changes in zonula occludens-1 and NEP, as well as Ab deposition in cell culture. 12 We hypothesized that HIV-1 subtype B patients would have lower CSF NEP levels compared with HIV1-C, because of the fact that HIV1-B Tat inhibits NEP. HIV+ patients would have lower CSF NEP levels compared with HIV2 subjects, with the lowest levels in patients with AD and highest levels in HIV2 healthy controls.
METHODS
This study, which was a cross-sectional survey of stored CSF samples, was approved by the University of California, San Diego (UCSD, San Diego, CA) Institutional Review Board (IRB), Hospital de Clínicas-Universidade Federal do Paraná (HC-UFPR, Curitiba, Paraná, Brazil) IRB, and the National Commission of Ethics in Research (CONEP).
Subjects
All participants signed consent forms approved by the IRBs in Brazil and USA. For patients with AD, the responsible caregiver signed the consent form. Samples of the CSF and serum were collected under a NIMH-funded protocol (R21 MH076651-01). The methods and the demographic and infection characteristics of the HIV+ patients were described previously. 13 A total of 105 CSF samples and 92 paired serum samples were analyzed.
HIV+ Participants
The HIV+ participants, n = 68, were recruited at the HC-UFPR. Individuals with opportunistic CNS infections were excluded. All volunteers provided blood and CSF samples and underwent serological testing to confirm HIV status before enrollment in accordance with previously published guidelines. 14 For participants with clinically resistant infection, the infecting HIV subtype was genotyped with pol sequences, whereas env sequences were used for all other participants. Genotyping indicated that 27 individuals were infected with HIV1-B and 40 were infected with non-B HIV1 subtypes (C, n = 26; BF, 10; BC, 1; CF, 1; and F, 2). In one participant, the HIV-1 subtype could not be genotyped.
HIV Negative Controls
Because lumbar punctures in uninfected volunteers are not allowed in Brazil, we recruited a control group of 13 agematched HIV2 individuals at the HIV Neurobehavioral Research Center, University of California, San Diego (HNRC-UCSD). They had no neurological comorbidities or cognitive complaints and tested negative on serological tests for hepatitis C and syphilis. The CSF cytochemical criteria for inclusion in the control group were white blood cell (WBC) count #5 cells/mm 3 , total protein #45 mg/dL, and glucose $55 mg/dL.
AD Participants
Twenty-four patients with AD were diagnosed by the Dementia Investigative team from the Cognitive Dysfunction Outclinic (Neurology Unit, HC-UFPR). All AD participants met the dementia criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM)-V 15 and criteria for probable AD of the National Institute on Aging-Alzheimer's Association. 16 Diagnostic methods of the AD group were described in detail previously. 11 
Laboratory Methods

CSF Biomarkers
NEP, activated as well as unactivated forms, was measured in the CSF and serum with an enzyme-linked immunosorbent assay (MyBioSource, San Diego, CA) with a quantitation range of 6.25-400 pg/mL. The minimum detectable dose of NEP was less than 2.51 pg/mL. Serum and CSF amyloid beta isoforms (Ab-38, 40, and 42) were assayed by electrochemiluminescence (MULTI-ARRAY, Meso Scale Diagnostics, LLC, Rockville, MD); CSF Ab-38, 40, and 42 levels were described previously. 13 All samples were assayed concurrently in duplicate according to the manufacturers' instructions. The acceptable coefficient of variation between duplicates was less than 20%. When the results were under the minimum low-detection limit determined by the manufacturers, the low-detection limit value was considered in the statistical analysis.
To enhance the specificity of the neuronal injury biomarkers, 17 combinations of these biomarkers in ratios and indexes were calculated in to a single value. Ratios between NEP and Ab-38, 40, 42, or total were calculated in CSF and serum, as well as CSF/serum indexes of these ratios; NEP index was calculated, NEP Index ¼ ðNEP CSF · Alb serum Þ=ðNEP serum · Alb CSF Þ.
Specimen Collection and Storage
CSF was collected by lumbar punctures with atraumatic spinal needles under aseptic conditions by a trained neurologist. The samples were collected in polypropylene tubes to avoid adherence of the proteins to the tube walls. CSF total protein, glucose, and WBC counts were measured with standard laboratory methods. All HIV+ and AD samples were collected at the same time interval of the day to limit diurnal variability. CSF and serum aliquots were frozen and stored at 280°C at HC-UFPR.
Data Analyses
Demographic and clinical variables were compared between the groups with Kruskal-Wallis test for continuous variables and Fisher exact test for binary and categorical variables. CSF, serum levels, ratios, and CSF/serum indexes of biomarkers were log 10 transformed to normalize their distributions before the statistical analyses. A hierarchy of comparisons was performed with the AD versus HIV+ groups as the primary comparison, HIV2 versus AD groups as the secondary comparison, and HIV2 versus HIV+ groups as the exploratory comparison, without adjustment for multiple comparisons. Age and sex were included as covariates in multivariable linear regression models if the P value was less than 0.2 in the adjusted model. If the age effect was significantly nonlinear, a smooth age effect was used within a generalized additive model. The P values within each class of biomarkers (CSF, serum, and CSF/serum) were then corrected for multiple testing with the Benjamini-Hochberg (BH) procedure.
The CSF and serum biomarkers, ratios, and CSF/serum indexes were then compared between the HIV1-B and HIV1-C groups. A multivariable model was applied to control for plasma HIV viral load suppression and nadir CD4 counts. As described above, the P values for the biomarker effects were corrected for multiple testing with the BH procedure.
The analysis results were considered statistically significant at the 5% alpha level. The differences between groups are presented as Cohen d effect sizes (and 95% confidence intervals). The statistical analyses were performed with R (version 3.2.3).
RESULTS
The demographic, clinical, and laboratorial characteristics of the groups studied are summarized in Tables 1 and 2 . Concerning the HIV(+) group, 55 cases (81%) had AIDS; median [interquartile range (IQR)] of the current CD4, 369 (201; 534) cells/mm 3 ; nadir CD4, 92 (37; 267) cells/mm 3 ; log plasma HIV RNA, 1.7 (1.7; 3.5); plasma HIV RNA , 50 copies per milliliter in 38 cases (56%). Combination antiretroviral therapy, mostly protease inhibitors, was prescribed to 55 participants (81%). Median (IQR) ARV CNS Penetration Effectiveness rank 19 was 8 (6; 9); adherence (AIDS Clinical Trials Group, ACTG, adherence questionnaire) 51 (93%). The demographic, clinical, and laboratorial characteristics of the groups HIV1-B and C are described in Table 3 . HIV subtype B-and C-infected individuals were similar in age, sex, and education. CSF samples of HIV subtype B-and C-infected individuals were comparable in total protein, WBC, and number of cases with pleocytosis (WBC .5 cell/ mm³); albumin; Q Alb ; CSF HIV RNA Log 10 ; and Log CSF HIV RNA ,1.7. The AD participants were probable AD; moderate dementia, Clinical Dementia Rating median (IQR) was 2 (2-2.5); severely decreased daily activity; and no associated depression (Table 1) .
NEP Levels in HIV1-B and HIV1-C Patients
Levels of CSF NEP (Table 4) were comparable for HIV1-C and B subtypes; serum NEP was numerically lower for HIV1-C than HIV1-B (P = 0.060) (Fig. 1A) . The ratio of NEP/Ab-40 in serum was lower for HIV1-C than HIV1-B (P = 0.032) (Fig. 1A) ; however, this difference was not significant after correction for multiple testing with the BH procedure.
Levels of serum Ab-38, 40, 42, and total were lower in HIV1-B group than HIV1-C, although do not reach 13 The ratios of NEP/Ab-42 and NEP/Ab-total in serum trended to significance (Table 4 ; Fig. 1A) . The CSF/serum index of NEP/Ab-40, NEP/Ab-42, and NEP/Ab-total was lower for HIV1-B than HIV1-C (P values 0.008, 0.005, and 0.017, respectively); corrected for multiple testing (BH) yielded significant P values and Cohen d effect sizes were moderate to high; (Table 4 ; Fig. 1B) . The results of CSF/ serum indexes corroborated the findings in serum.
NEP Levels in HIV+, HIV2, and Patients With AD
Levels of CSF and serum NEP for the different groups are shown in Table 5 ; CSF NEP was comparable for the 3 groups studied. In serum, NEP levels were higher in HIV+ than AD and HIV2, (0.007 and 0.056, respectively).
DISCUSSION
This is the first study to analyze NEP in patients with HIV1 non-B subtypes. CSF and serum NEP were comparable for HIV1-C and B subtypes. However, the ratio of NEP/Ab40 in serum was lower in HIV1-C than B. Lower NEP/Ab40 in subtype C is consistent with less cleavage of Ab40 with greater tissue deposition of Ab40. This is also supported by previous findings of lower CSF Ab42 in subtype C, reported by our research group. 13 However, the findings overall are counterintuitive. We expected the defective Tat in subtype C to yield less inhibition of NEP with correspondingly lower tissue deposition of Ab and therefore higher levels of Ab in CSF. Previous studies on which this hypothesis was based were experimental. 6, 7 Our analysis of human samples did not confirm the in vitro findings. The Tat sequences used in the previous in vitro studies may have differed from those in our clinical samples. Other factors that could explain these differences include the use of antiretroviral medications, which may affect amyloid metabolism. More studies need to be performed to elucidate the impact of HIV subtypes on NEP metabolism. The comparisons of these markers could provide very useful information that will lead to expanded studies on neuropathology associated with different HIV subtypes, especially in the aging population.
Based on the present results, we conclude that NEP was driving the results, as the values of serum NEP trend to be lower in HIV1-C than B and were supported by the differences between the ratios in serum and CSF/serum indexes. Although numerical values of serum Ab isoforms were lower in HIV1-B group than HIV1-C, probably they do not determine the results of ratios and indexes because they are not statistically significant.
CSF NEP was comparable for the HIV+, HIV(2), and AD; in serum, NEP levels were higher on HIV than AD and CTRL.
Our findings did not confirm the hypothesis that CSF NEP levels in HIV would be in-between those in AD (low) and in HIV2 controls (high). There are several potential explanations for this finding. First, there is disagreement in the literature on NEP levels in AD. For example, one study showed reduced CSF NEP activity levels in early (prodromal) AD, 20 whereas another demonstrated that brain tissue NEP levels were increased in AD. 21 Thus NEP levels may change during the course of AD. The patients we studied had wellestablished AD, more advanced than in the Maruyama et al 20 study. Our failure to find higher levels of NEP in HIV+ compared with AD therefore might be related to the stage of AD in our patients. Alternatively, CSF NEP levels may not correlate well with NEP levels and activity within brain tissue.
NEP, also known as CD10 or enkephalinase, is a type II transmembrane bound zinc metalloendopeptidase with relatively broad substrate specificity. Its molecular weight is 85.5 (85-110 kDa) kD, 10, 22 and the hydrodynamic radius or Stokes radius is 56 Å. Because NEP is a high molecular weight molecule, diffusion does not occur through a functional blood-CSF barrier. A dysfunctional blood-CSF barrier, however, might result in diffusion of NEP from blood to CSF, several studies have noted marked increases in diffuse amyloid plaques in the HIV(+) group compared with HIV(2) age-matched controls. 4, 6, 23, 24 This suggested that an inflammatory response in the brain to HIV-1 infection could lead to dysregulation of amyloid processing in the setting of HIV infection 25 and facilitate amyloid plaque formation.
NEP is mainly synthesized in various types of cells outside brain, is widely distributed in the body, and normally expressed by a variety of tissues. 10 In brain, it is expressed by activated astrocytes 26 and microglia. 27 For proteins derived primarily from blood, as NEP, the CSF/serum quotients may be informative. To estimate NEP intrathecal synthesis, indexes between CSF and serum and the NEP index were calculated. 28 Cleavage by NEP greatly reduces the aggregation tendency and neurotoxicity of the resulting fragments 29 as demonstrated for cleavage by the peptidase insulin. 30 NEP is the dominant Ab peptide-degrading enzyme in the brain, chiefly Ab-40, but also Ab-42 and other Ab isoforms. 31 
HIV-1-Infected Patients
HIV-1 markedly increased the endogenous Ab levels and accumulation of exogenous Ab in an HIV-1-exposure model of brain microvascular endothelial cells. 32 HIV has great impact on Ab metabolism; Ab deposition differs in AD and HIV-1 brains. Although extracellular amyloid plaques are the major amyloid pathology in AD, intraneuronal amyloid accumulation or diffuse perivascular amyloid depositions are more characteristic for HIV-associated neurocognitive disorder. 33 The mechanisms underlying the interactions between Ab and HIV-1 infection are not fully understood, but several factors and/or pathways are likely to be involved. It has been hypothesized that aging, HIV-1 infection, and the secondary effects of ART may all contribute to brain Ab accumulation in neurons and in perivascular space. 4 HIV-1 can increase Ab levels by increasing its synthesis, decreasing its degradation, or changing its transport mechanisms across the blood-brain barrier, leading to its accumulation in the brain. 33, 34 Several HIV proteins are amyloidogenic, such as gp120, 24, 35 gp41, 36 Tat, 6, 7, 24, 37 or Nef. 38 Mononuclear phagocytes, which are macrophages and microglia, that are infected by HIV play a pivotal role in Ab degradation through the expression and execution of 2 endopeptidases, NEP, and insulin-degrading enzyme. 37 In addition, multiple studies have described the amyloidogenic interference of ART. 39 Tat, which is the main HIV amyloidogenic protein, interferes with Ab cleavage (chiefly through NEP) and amyloid peptide reuptake and clearance. HIV-1 Tat protein increases Ab levels in cell culture. 6 In addition, HIV-1 Tat, specifically HIV1-B, increases Ab-40 levels in neuronal cell cultures by inhibiting NEP. 6, 7, 24, 37 HIV-1-infected cells actively secrete Tat, a viral transactivating transcription factor. 3 At micromolar concentrations, in vitro, HIV-1 Tat inhibits the major Ab-degrading enzyme, NEP, a neuronal endopeptidase. These findings imply that premature accumulation of Ab in the HIV-1-infected population will increase the risk of dementia compared with the normal aging population.
Tat release continues even in patients with durable virologic suppression; tat was detected in the CSF of individuals with undetectable HIV viral load in the blood and CSF. 40 In transgenic AD mice having HIV-1 Tatexpressing astrocytes, more neurodegeneration and Ab deposition were observed compared with mice not expressing astrocytic Tat serine. 41 Tat Interference on Ab-42 Clearance Tat inhibited NEP activity by 80%, causing amyloid b (Ab) accumulation. 6 Comparison of the overlapping Tat sequences demonstrated that NEP maximal inhibition required the amino acid sequence KCCF (amino acids [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . 7 Studies about CSF NEP on HIV are poorly reported on the literature. The only 2 in vitro studies that showed that cysteine-rich peptides derived from the Tat protein are inhibitors of NEP were performed with HIV clade B. 6, 7 Although the cysteine-rich domain is described as highly conserved among different HIV-1 strains, in HIV clade C that infects the largest populations around the world, the cysteine residue in position 31 is mutated to a serine. 9 This study is not free of limitations. Samples from the HIV(2) controls were from a different study site. Although the HIV(+) and HIV(2) did not differ on race/ethnicity, Brazilian populations have a higher genetic heterogeneity than those in the United States. This limitation was not applicable to the comparison between subtypes B and C because all the participants were from the same geographical region in Brazil and were similar in age and sex. The study was limited by its cross-sectional design. A longitudinal study might be able to predict the development of HIV-associated neurocognitive disorders in patients without clear symptoms. Vulnerability to AD is greatest in older individuals; our study did not include a substantial number of older HIV(+). We did not assess HIV(+) patients with known AD, although reports of patients with both conditions are rare. The HIV(2) group was younger than the AD group because this group was ageand sex-matched with the HIV(+) group. Future longitudinal studies that include older HIV(+) individuals are necessary to evaluate the effects of HIV on the NEP pathway. Finally, the assay used here quantified activated and unactivated NEP forms but did not directly assess NEP activity.
This study had several strengths; this was the first study to examine HIV1-C patients and investigate HIV-subtype effects on NEP metabolism. The sample size was sufficient for power analysis because absolute values of Cohen d effect sizes were medium to large. HIV+ and AD patients were from the same center and were analyzed at the same period; both healthy and disease controls were used. HIV positive and HIV2 are age matched, and this is important as NEP becomes inactivated and down-regulated with aging. 10 In conclusion, the results of this study have shown that HIV infection affects serum NEP function on a subtypedependent pattern; HIV subtypes C and B differed, suggesting less destruction of Ab, which might accumulate more in HIV1-C; potentially increasing risk of neurocognitive impairment with aging in HIV1-C.
